Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression

Prostate

Volumn 33, Issue 2, 1997, Pages 97-104

  Hsieh, Tze Chen ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

4 HPR; Androgen receptor; Prostate growth; Prostate specific antigen

Indexed keywords

FENRETINIDE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER PREVENTION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; GROWTH REGULATION; HUMAN; HUMAN CELL; MALE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CATTLE; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DNA FRAGMENTATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FENRETINIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0030819128     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19971001)33:2<97::AID-PROS3>3.0.CO;2-J     Document Type: Article

References (30)

1. Greenwald P, Kelloff G, Burch-Whitman C, Kramer S: Chemoprevention. CA 1995;45:31-49.
2. Lange PH: Early detection for prostate cancer. JNCI 1991;83: 1199-1201.
3. Stearns ME, Wang M: Type IV collagenase (M(r) 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res 1993;53:878-883.
4. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122: 552-562.
5. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 1992;10:839-864.
6. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD, Fenton RM, Connaghan GD, Hittelman WN, Poplack DG: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 1992;10:1666-1673.
7. Moon RC, Mehta RG, Detrisac CJ: Retinoids as chemopreventive agents for breast cancer. Cancer Detect Prev 1992;16:73-79.
8. Pollard M, Luckert PH: The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett 1991;59:159-163.
9. Igawa M, Tanabe T, Chodak GW, Rukstalis DB: N-(4-hydroxyphenyl) retinamide induces cell cycle-specific growth inhibition in PC3 cells. Prostate 1994;24:299-305.
10. Mariotti A, Marcora E, Bunone G, Costa A, Veronesi U, Pierotti MA, Valle GD: N-(4-hydroxyphenyl)retinamide: A potent inducer of apoptosis in human neuroblastoma cells. JNCI 1994; 86:1245-1247.
11. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG: Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res 1995;55:853-861.
12. Delia D, Aiello A, Lombardi L, Pekicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U, Pierotti MA: N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-6041.
13. Gong J, Traganos F, Darzynkiewicz Z: A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994;218:314-319.
14. Zeballos GA, An S, Wu JM: Endothelin-1 secretion by human fibroblasts in culture: Effects of cell density and IFN-β. Biochem Int 1991;25:845-852.
15. Cui Y, An S, Jabr S, Maturana JA, Wu JM, Gutstein WH: The anti-proliferative effects of nicotinamide and 3-aminobenzamide on human smooth muscle cells in vitro. Biochem Mol Biol Int 1993;31:935-944.
16. Evans GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-128.
17. Khosla S, Oursler MJ, Schroeder MJ, Eberhardt NL: Transforming growth factor-β1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid level. Endocrinology 1994;135:1887-1893.
18. Desjardins LM, MacManus JP: An adherent cell model to study different stages of apoptosis. Exp Cell Res 1995;216:380-387.
19. D'Angio GJ, Evans AE, Koop CE: Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971;1: 1046-1049.
20. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
21. Williams GT: Programmed cell death. Apoptosis and oncogenesis. Cell 1991;65:1097-1098.
22. Schiffer D, Cavalla P, Chio A, Giordana MT, Marino S, Mauro A, Migheli A: Tumor cell proliferation and apoptosis in medullo-blastoma. Acta Neuropathol (Berl) 1994;87:362-370.
23. Cher ML, Chew K, Rosenau W, Carroll PR: Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995; 26:87-93.
24. Qiao L, Pizzolo G, Melamed MR: Effects of selected chemotherapeutic agents on PCNA expression in prostate carcinoma cell lines. Urol Res 1994;22:171-176.
25. Spires SE, Banks ER, Davey DD, Jennings CD, Wood DP, Cibull ML: Proliferating cell nuclear antigen in prostatic adenocarcinoma: Correlation with established prognostic indicators. Urology 1994;43:660-666.
26. Cohen P, Peehl DM, Graves HC, Rosenfeld RG: Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142:407-415.
27. Birnbaum RS, Ware JL, Plymate SR: Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. J Endocrinol 1994;141:535-540.
28. Kanety H, Madjar Y, Dagan Y, Kevi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-233.
29. Henttu P, Vihko P: Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol 1992;41:349-360.
30. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine E, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-1084.